Ronald Bukowski

1.3k total citations · 1 hit paper
23 papers, 999 citations indexed

About

Ronald Bukowski is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ronald Bukowski has authored 23 papers receiving a total of 999 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 7 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ronald Bukowski's work include Cancer Treatment and Pharmacology (4 papers), Immunotherapy and Immune Responses (4 papers) and Lung Cancer Research Studies (3 papers). Ronald Bukowski is often cited by papers focused on Cancer Treatment and Pharmacology (4 papers), Immunotherapy and Immune Responses (4 papers) and Lung Cancer Research Studies (3 papers). Ronald Bukowski collaborates with scholars based in United States, Netherlands and India. Ronald Bukowski's co-authors include Simon Tchekmedyian, Carolyn Taylor, Saroj Vadhan‐Raj, John A. Glaspy, Vladimir Kolenko, James H. Finke, Robert G. Uzzo, Martha K. Cathcart, Patricia Rayman and John J. O’Shea and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Ronald Bukowski

23 papers receiving 947 citations

Hit Papers

Impact of therapy with epoetin alfa on clinical outcomes ... 1997 2026 2006 2016 1997 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.
    1997 567 citations John A. Glaspy, Ronald Bukowski et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ronald Bukowski United States 10 481 359 174 133 132 23 999
T J MacVittie United States 19 674 1.4× 336 0.9× 297 1.7× 224 1.7× 150 1.1× 41 1.4k
Mammo Amare United States 14 362 0.8× 216 0.6× 92 0.5× 238 1.8× 81 0.6× 28 827
Michaëla Semeraro France 17 94 0.2× 319 0.9× 276 1.6× 224 1.7× 75 0.6× 34 989
Andrija Bogdanović Serbia 17 466 1.0× 141 0.4× 162 0.9× 294 2.2× 279 2.1× 96 894
Sven-Åge Killmann Denmark 16 288 0.6× 136 0.4× 173 1.0× 145 1.1× 108 0.8× 37 811
Lyonel G. Israels Canada 18 269 0.6× 166 0.5× 128 0.7× 262 2.0× 267 2.0× 36 814
Thomas A Ratko United States 16 255 0.5× 143 0.4× 104 0.6× 172 1.3× 28 0.2× 32 813
Driss Chaoui France 16 324 0.7× 478 1.3× 54 0.3× 318 2.4× 196 1.5× 29 1.1k
Marleen Luten Netherlands 9 295 0.6× 45 0.1× 66 0.4× 161 1.2× 144 1.1× 12 891
R Goudsmit Netherlands 15 475 1.0× 118 0.3× 66 0.4× 78 0.6× 268 2.0× 43 736

Countries citing papers authored by Ronald Bukowski

Since Specialization
Citations

This map shows the geographic impact of Ronald Bukowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald Bukowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald Bukowski more than expected).

Fields of papers citing papers by Ronald Bukowski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronald Bukowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald Bukowski. The network helps show where Ronald Bukowski may publish in the future.

Co-authorship network of co-authors of Ronald Bukowski

This figure shows the co-authorship network connecting the top 25 collaborators of Ronald Bukowski. A scholar is included among the top collaborators of Ronald Bukowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronald Bukowski. Ronald Bukowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vaziri, S. A., Michael S. Lynch, Brian Schwartz, et al.. (2006). Anti-proliferative effects of sorafenib in clear cell renal cell carcinoma (CCRCC) cell lines: Relationship to von Hippel Lindau protein (pVHL) expression and hypoxia. Journal of Clinical Oncology. 24(18_suppl). 4601–4601. 4 indexed citations
2.
Rojas‐Espaillat, Luis, Denise Uyar, Dale Grabowski, et al.. (2005). Apoptotic pathways induced by ixabepilone in paclitaxel-refractory ovarian carcinoma cells. Cancer Research. 65. 1257–1257. 8 indexed citations
3.
Thakkar, Sachin G., Peter S. Heeger, Gottfried Himmler, et al.. (2004). A phase Ib trial of an anti-idiotypic vaccine for Lewis Y (IGN 301) administered subcutaneously in patients with refractory solid tumors. Journal of Clinical Oncology. 22(14_suppl). 2586–2586. 2 indexed citations
4.
Kalmadi, Sujith, Tarek Mekhail, David J. Adelstein, et al.. (2004). Weekly docetaxel-gemcitabine as first-line treatment in advanced non-small cell lung cancer: Preliminary results of a phase II study. Journal of Clinical Oncology. 22(14_suppl). 7236–7236. 1 indexed citations
5.
Zhu, Andrew X., Ronald Bukowski, A. Craig Lockhart, et al.. (2004). Phase 1 trial of oral MAC-321 in subjects with advanced malignant solid tumors. Journal of Clinical Oncology. 22(14_suppl). 2040–2040. 1 indexed citations
6.
7.
Ganapathi, Ram, S. A. Vaziri, Masahiro Tabata, et al.. (2002). Inhibition of NF-κB and Proteasome Activity in Tumors: Can We Improve the Therapeutic Potential of Topoisomerase I and Topoisomerase II Poisons. Current Pharmaceutical Design. 8(22). 1945–1958. 7 indexed citations
8.
Uzzo, Robert G., Vladimir Kolenko, Christopher J. Froelich, et al.. (2001). The T cell death knell: immune-mediated tumor death in renal cell carcinoma.. PubMed. 7(10). 3276–81. 15 indexed citations
9.
Sandstrom, Kate, Paul Elson, Denise McLain, et al.. (2001). GM-CSF safety and effects in the management of advanced/refractory multiple myeloma patients: a phase I trial. Journal of Cancer Research and Clinical Oncology. 127(10). 619–624. 4 indexed citations
10.
Kolenko, Vladimir, Robert G. Uzzo, Ronald Bukowski, & James H. Finke. (2000). Caspase-dependent and -independent death pathways in cancer therapy. APOPTOSIS. 5(1). 17–20. 68 indexed citations
11.
12.
Bukowski, Ronald. (1999). Cytoprotection in the treatment of pediatric cancer: Review of current strategies in adults and their application to children. Medical and Pediatric Oncology. 32(2). 124–134. 12 indexed citations
13.
14.
Peereboom, David M., G. Thomas Budd, Thomas Olencki, et al.. (1998). Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer. Investigational New Drugs. 16(3). 255–258. 8 indexed citations
15.
Glaspy, John A., et al.. (1997). Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.. Journal of Clinical Oncology. 15(3). 1218–1234. 567 indexed citations breakdown →
16.
Kolenko, Vladimir, Qing Wang, John J. O’Shea, et al.. (1997). Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas. The Journal of Immunology. 159(6). 3057–3067. 66 indexed citations
17.
Splinter, Ted A.W., Howard I. Scher, L. Denis, et al.. (1992). The Prognostic Value of the Pathological Response to Combination Chemotherapy before Cystectomy in Patients with Invasive Bladder Cancer. The Journal of Urology. 147(3 Part 1). 606–608. 99 indexed citations
18.
Denis, L., Ronald Bukowski, Mark S. Soloway, et al.. (1990). The prognostic value of the pT-category after combination chemotherapy for patients with invasive bladder cancer who underwent cystectomy. EORTC-GU group.. PubMed. 353. 219–24. 21 indexed citations
19.
Ganapathi, Ram, et al.. (1985). Analysis of heterogeneity in daunorubicin uptake by human leukemia cells using laser flow cytometry. Investigational New Drugs. 3(3). 273–277. 6 indexed citations
20.
Schacter, Bernice, et al.. (1977). HLA-B7 association with low spontaneous cell-mediated cytotoxicity (Sp-CMC) to renal cell carcinoma cell lines.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 9(4). 1849–51. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T J MacVittie Breakdown of academic impact, for papers by Mammo Amare Breakdown of academic impact, for papers by Michaëla Semeraro Breakdown of academic impact, for papers by Andrija Bogdanović Breakdown of academic impact, for papers by Sven-Åge Killmann Breakdown of academic impact, for papers by Lyonel G. Israels Breakdown of academic impact, for papers by Thomas A Ratko Breakdown of academic impact, for papers by Driss Chaoui Breakdown of academic impact, for papers by Marleen Luten Breakdown of academic impact, for papers by R Goudsmit
Rankless by CCL
2026